Latest From ResMed Inc.
The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.
Sleep apnea treatment company ResMed Corp. will pay $39.5m to settle allegations that it violated the False Claims Act by giving free or discounted goods and services to distributors and health-care providers to encourage the use of the firm’s devices.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
The winners of this year’s Medtech Insight Awards were revealed last night at a glittery ceremony in Boston. The awards, held in partnership with the MedTech Conference, recognized excellence and achievement across the industry.
- Diagnostic Equipment & Supplies
- Monitoring Equipment & Devices
- Therapeutic Areas
- Neurology, Nervous System
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
- ResMed Inc.
- Senior Management
Michael Farrell, CEO
Robert Douglas, Pres. & COO
- Contact Info
Phone: (858) 836-5000
9001 Spectrum Ctr. Blvd.
San Diego, CA 92123
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.